Sands Capital Management LLC Makes New Investment in Boston Scientific Corporation $BSX

Posted by Geri Gentry on Jun 15th, 2026

Boston Scientific logo Sands Capital Management LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 4th quarter, HoldingsChannel reports. The fund acquired 805,164 shares of the medical equipment provider’s stock, valued at approximately $76,772,000.

Several other hedge funds have also bought and sold shares of BSX. Murphy & Mullick Capital Management Corp boosted its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Colonial Trust Co SC boosted its position in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank boosted its position in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Analyst Ratings Changes

Several equities research analysts have commented on the company. Truist Financial lowered their price objective on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, June 4th. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Friday. Needham & Company LLC restated a “buy” rating and issued a $77.00 price objective on shares of Boston Scientific in a research report on Monday, May 18th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

View Our Latest Research Report on BSX

Boston Scientific Price Performance

NYSE:BSX opened at $46.83 on Monday. Boston Scientific Corporation has a one year low of $45.99 and a one year high of $109.50. The stock has a market cap of $69.60 billion, a PE ratio of 19.59, a P/E/G ratio of 0.89 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a 50 day moving average price of $56.37 and a 200 day moving average price of $74.78.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.